DEA’s Broader Marijuana Schedule III Hearing Opens June 29 With Seven Outside Participants

A June 29 start, a July 15 stop, and seven formal voices

The next federal hearing over marijuana’s status under U.S. drug law opens Monday, June 29, and the schedule is now fixed. The Drug Enforcement Administration says the proceeding will begin at 9:00 a.m. Eastern in Arlington, Virginia, and conclude no later than July 15. It has also fixed the formal participant list: seven selected interested persons will appear alongside the government.

That is news because this is the first hard federal process date since the Justice Department’s narrower April order moved FDA-approved marijuana products and certain state-licensed medical marijuana products into Schedule III. That April step was real, but limited. The hearing starting now is about the unresolved part: whether marijuana more broadly, beyond that already-rescheduled medical lane, should also be transferred to Schedule III.

In plain terms, Washington has split marijuana policy into two tracks. One track already gave some federally recognized room to medical products that fit the April order. The other track, the one now heading into a hearing room, will determine whether the federal government is willing to extend that treatment further.

For the cannabis industry, that makes the calendar and the room itself matter. A fixed hearing window tells operators, investors, state officials, and policy watchers when the next federal record will be built. The participant list shows whose concerns are likely to dominate it. Those are not minor details in an administrative proceeding. They shape what evidence is heard, what arguments are pressed, and what kind of final decision the agency can later defend.

The federal notice of hearing in April established June 29 as the opening date. The June 25 logistics release added the practical detail: the hearing will run from June 29 through July 15 and public access will be limited. A preliminary order from the administrative law judge, the official who manages the hearing process, set attendance and filing procedures and repeated the designated participant structure.

So the immediate picture is clear even if the outcome is not. The federal government has moved past general talk and into a bounded evidentiary phase. There is a room, a start time, an end point, a controlled public process, and a short list of participants who will formally help build the record.

Why this hearing exists after April’s medical-only Schedule III order

The hearing only makes sense if the April split is understood first. On April 23, the Justice Department announced that FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license would be placed in Schedule III. That was a narrower federal move than many operators had spent years anticipating. It did not simply reclassify all marijuana at once.

Schedule III is one category within the federal controlled substances system, the set of legal classifications the government uses to rank drugs and attach rules around handling, research, prescribing, and criminal enforcement. Moving a substance from Schedule I to Schedule III is not a cosmetic change. It signals a lower level of federal restriction than Schedule I, even though it still keeps the substance under tight control.

What April did, however, was not the broad rewrite many state cannabis businesses wanted. It applied to FDA-approved marijuana products, which are already a narrow category, and to products containing marijuana that are subject to a qualifying state-issued medical license. Adult-use markets were not pulled clearly into that same lane. Neither were all marijuana products in all state systems.

That is why a second process is now underway. The April 28 Federal Register notice formally opened a hearing on the proposed broader rescheduling of marijuana. In practice, that means the government is creating a public administrative record before deciding whether to move beyond the medical-only step.

This is more than paperwork. In a federal administrative hearing, the record matters because it becomes the basis for the agency’s final action and the first line of defense if that action is later challenged. The hearing is where selected participants can present testimony, submit evidence, and test competing claims under a formal process rather than through press releases or political statements.

The structure also explains why the participant slate matters so much. Not everyone who cares about marijuana policy gets equal standing in a hearing like this. The agency selects “interested persons,” which in practice means a limited number of outside participants who receive a formal role in the proceeding. Those participants are not merely observers. They are part of how the record is made.

DEA’s public regulatory actions page names the seven selected interested persons. They are the National Drug & Alcohol Screening Association; the Tennessee Bureau of Investigation; Smart Approaches to Marijuana; a grouped state participation by Nebraska, Idaho, Indiana, and Louisiana; DUID Victim Voices; Kenneth Finn, MD; and Phillip A. Drum, PharmD.

Even before any witness speaks, that list says something important about the frame of the proceeding. The selected voices lean toward public safety, law enforcement, drug testing, medical skepticism, and pharmacy or physician testimony. There is no obvious cluster of state-licensed operators, dispensary groups, cultivators, or adult-use trade representatives in the formal outside lineup announced by DEA.

That does not predetermine the result. The government will present its own case, and the administrative law judge’s job is to manage procedure, not to choose policy. But it does show that the next phase of the marijuana rescheduling debate is not being built around the operating realities of licensed commercial markets. It is being built around a narrower federal evidentiary frame.

The participant list says more than the calendar does

For industry readers, the most revealing fact may not be that the hearing starts on June 29. It may be who is formally in the room when it starts.

The National Drug & Alcohol Screening Association points toward workplace testing and compliance concerns, especially the continuing role of marijuana in employment screening and impairment policy. The Tennessee Bureau of Investigation and the grouped participation by Nebraska, Idaho, Indiana, and Louisiana suggest a strong law enforcement and state-government presence. Smart Approaches to Marijuana has long argued against broad normalization of cannabis policy. DUID Victim Voices centers driving-under-the-influence harms. Kenneth Finn and Phillip Drum bring medical and pharmacy credentials that fit a debate over accepted medical use, safety, and controls.

Taken together, those participants are likely to pull the hearing toward a familiar set of federal concerns: public safety, misuse, impaired driving, youth exposure, clinical evidence, and the practical problem of measuring impairment. All of those issues are real. But they are not the same as the questions that dominate boardrooms and state licensing offices, such as how mixed medical and adult-use businesses function, how product categories overlap, how compliance systems are built, or how federal categories line up with state law.

That gap matters because the modern U.S. cannabis market is not organized the way this participant list is. Many operators run medical and adult-use businesses inside the same company structure. Many states have linked supply chains, overlapping cultivation platforms, shared brands, and common retail footprints. A hearing built around a narrow medical category on one side and broader public safety objections on the other may not capture how integrated the actual market has become.

The April order already sharpened that divide. Qualifying state-licensed medical products were brought into Schedule III. Adult-use products were not clearly carried with them. For companies that operate in both lanes, that creates an awkward federal split inside a business model that has mostly been built on convergence. A company can be medical in one part of its state operation and adult-use in another, but federal classification does not neatly follow the same commercial logic.

That is why this hearing matters well beyond legal theory. It affects how operators think about future product planning, compliance architecture, market access, and the value of medical programs inside states that also allow adult-use sales. It affects how investors model federal policy risk across multistate operators with blended revenue streams. It affects how state regulators think about their own medical systems if broader federal rescheduling either does or does not arrive.

It also affects the politics of state medical programs. The April move gave medical marijuana, at least in qualifying licensed form, a more distinct federal foothold. If broader marijuana is not moved the same way, states may see renewed pressure either to preserve a meaningful medical channel or to clarify the practical divide between medical and adult-use markets. In some jurisdictions that could strengthen medical program identity. In others it could expose how thin that distinction has already become.

The short hearing window adds another layer. June 29 to July 15 is enough time to build a record, but not enough time to resolve every scientific, commercial, and legal conflict around marijuana policy. That makes this a disciplined federal process, not an open-ended market consultation. The limited-capacity public access described by DEA reinforces that point. This is a managed administrative forum with a defined participant class, not a broad national listening exercise.

For policy watchers, that means the hearing should be read carefully but not romantically. The proceeding can move the federal debate forward. It can also narrow it. A record built mainly around public safety objections and medical credentialing may still support broader rescheduling, but it will do so on the government’s chosen terrain rather than on the industry’s preferred one.

Federal marijuana policy is moving by slices, not by one grand rewrite

The larger lesson from this hearing is not speed. It is segmentation.

Federal marijuana policy is advancing in pieces. First came the April medical-only order, which carved out FDA-approved products and qualifying state-licensed medical marijuana products for Schedule III treatment while keeping strict federal controls in place. Now comes a hearing on whether the rest of marijuana should follow. That is not the clean nationwide reset many political slogans imply. It is a layered administrative approach in which the government recognizes one part of the market, tests another part in a hearing, and leaves large operational questions for later.

That sliced approach has consequences. It gives medical marijuana a clearer federal status than adult-use marijuana, at least for now. It forces companies and regulators to think in narrower categories than the retail market usually does. It also increases the odds that federal reform, if it comes, will arrive with conditions, distinctions, and transitional problems rather than as one simple declaration.

The participant list supports that reading. The government has not assembled a panel that looks like the current licensed cannabis economy. It has assembled one that looks like a federal evidentiary challenge. That means the question is not merely whether marijuana is popular in the states or commercially entrenched. The question, as this process is structured, is whether the federal government can justify a broader Schedule III decision on a record built to survive institutional scrutiny.

There is discipline in that. There is also distance. The states built real cannabis markets years before Washington was prepared to redraw federal classifications. The hearing opening on June 29 does not close that gap. It formalizes it.

By July 15, the hearing is scheduled to be over. The uncertainty will not be. The record will still need to be weighed, the agency will still need to decide what comes next, and the split between medical recognition and broader marijuana status will still define the market’s federal problem. This is a serious step, but it is not the end of the argument.

The practical conclusion is stark. The United States is no longer treating marijuana as one single federal question. It is treating marijuana as a set of narrower questions, answered in sequence, under tightly controlled process. That may be the only way this government can move. It is also why each date, each order, and each seat in the hearing room now carries more weight than the headlines usually admit.